Baxter International Inc. (BAX)
Chart Events
Performance Outlook
| Previous Close | 81.94 |
| Open | 82.32 |
| Bid | 82.68 x 800 |
| Ask | 82.71 x 1000 |
| Day's Range | 81.70 - 84.30 |
| 52 Week Range | 73.12 - 88.32 |
| Volume | 1,689,608 |
| Avg. Volume | 3,281,633 |
| Market Cap | 41.334B |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | 39.71 |
| EPS (TTM) | 2.07 |
| Earnings Date | Oct 27, 2021 - Nov 01, 2021 |
| Forward Dividend & Yield | 1.12 (1.41%) |
| Ex-Dividend Date | Sep 02, 2021 |
| 1y Target Est | 93.64 |
- Business Wire
Baxter Reports Third-Quarter 2021 Results
DEERFIELD, Ill., October 28, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021.
- Zacks
Baxter (BAX) to Report Q3 Earnings: What's in the Offing?
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
- Business Wire
Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury
DEERFIELD, Ill. & MARCY L’ETOILE, France, October 21, 2021--Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR™ CCL1
